BDBM305803 2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile::US10144738, Example 2::US10822341, Example 2::US11472809, Example 2

SMILES OCc1cc(n[nH]1)-c1cn2nccc2c(n1)-c1cnn(c1)C1(CC#N)CN(CC2CC2)C1

InChI Key InChIKey=LLGMLMVYBOJRCA-UHFFFAOYSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 305803   

TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  62nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  299nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  62nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  1.06E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  299nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  62nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  1.06E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  299nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  62nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  1.06E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  299nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM305803(2-(1-(Cyclopropylmethyl)-3-(4-(6-(5-(hydroxymethyl...)
Affinity DataIC50:  1.06E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent